Background: Nasal carriage of Staphylococcus aureus (NCSA) is frequent in patients with allergic rhinitis (AR). Allergen immunotherapy is safe and effective in the treatment of AR. Objective: The present work aims to assess the effect of NCSA on the clinical response to immunotherapy (IT) in AR patients. Methodology: Assessment of symptom severity was done by visual analogue scale in 25 NCSA-positive and 25 NCSA-negative AR patients. Patients were treated by cluster IT for 8 weeks after which symptom severity was reassessed. Results: Before IT, NCSA-positive patients showed significant increase in rhinorrhea, sneezing, and nasal blockage than NCSA-negative patients. No significant difference was observed in non-nasal symptoms or total symptom severity scores. After IT, there was no difference in the severity of nasal and non-nasal symptoms between the two groups. Clinical improvement was more noticeable in NCSA-positive than NCSA-negative patients; however, the difference is non-significant. Conclusion: NCSA does not affect the clinical response to immunotherapy in AR patients.